If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.65    0.00 (0.00%)
Bid:
1.30
Ask:
2.06
Spread: 0.76 (58.462%)
Market Cap: £5.79m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

License Agreement

9 Apr 2010 07:00

RNS Number : 9292J
Proteome Sciences PLC
09 April 2010
 



 

 

Proteome Sciences plc

ProteoPrep License agreement with Sigma-Aldrich

 

 

9th April, 2010 Proteome Sciences plc ("Proteome Sciences") is pleased to announce that it has entered into a non-exclusive license agreement with Sigma-Aldrich Corporation ("Sigma") under which Sigma will be able to continue selling products under Proteome's registered trademark ProteoPrep® in Europe, Japan and Australia. Sigma is the world's largest supplier of research biochemicals and organic chemicals with over one million customers.

 

There are currently eleven ProteoPrep® kits available from Sigma and the license will also include all future products sold under the ProteoPrep® trademark that contain chemicals and reagents for the disruption of cells, tissues or other biological material and the extraction of biological molecules like proteins, lipids and carbohydrates. It also covers methods and processes relating to assays for the diagnosis of diseases and chemical markers determining targets for drugs and for determining proteins and peptides by disruption of cells, tissues or other biological material. The license provides Proteome with a signature fee and royalties on all ProteoPrep® sales in the jurisdictions listed above.

 

Commenting on the license Christopher Pearce, Chief Executive of Proteome Sciences said:

 

"We are delighted to have concluded the license with Sigma-Aldrich Corporation for the ProteoPrep® trademark and look forward to receiving this new stream of revenue from royalties generated by their successful and expanding range of ProteoPrep® products."

 

 

 

- End -

 

 

For further information please contact:

 

Proteome Sciences plc

www.proteomics.com Tel: +44 (0)1932 865065

Christopher Pearce, Chief Executive Officer christopher.pearce@proteomics.com 

James Malthouse, Finance Director james.malthouse@proteomics.com 

Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com 

 

Nominated Adviser

Singer Capital Markets Limited

Shaun Dobson/Claes Spång

Tel: +44 (0)20 3205 7500

 

Public Relations

IKON Associates Redleaf Communications Limited

Adrian Shaw Anna Dunkin/Lucy Salaman

Tel: +44 (0)1483 535102 Tel: +44 (0)20 7566 6700

Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com 

Email: adrian@ikonassociates.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRLLFLRSDITIII
Date   Source Headline
3rd Aug 20227:00 amRNSMilestone towards Single Cell Proteomics services
26th May 20229:04 amRNSChange of Registered Office
16th May 20221:24 pmRNSResult of AGM
16th May 20227:00 amRNSAGM Statement
12th May 20227:00 amRNSSubstantial Contract Win
26th Apr 20224:45 pmRNSDirector/PDMR Shareholding
21st Apr 20225:13 pmRNSDirector/PDMR Shareholding
11th Apr 20227:00 amRNSInvestor Presentation
1st Apr 20226:01 pmRNSDirector shareholding
31st Mar 20227:09 amRNSFinal Results
30th Mar 202211:24 amRNSLoan amendment
29th Mar 20227:00 amRNSNotice of Results
16th Feb 20224:40 pmRNSSecond Price Monitoring Extn
16th Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading Update
31st Dec 202112:36 pmRNSPrice Monitoring Extension
20th Dec 20217:00 amRNSSubstantial Contract Win
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20214:36 pmRNSPrice Monitoring Extension
26th Nov 20214:36 pmRNSPrice Monitoring Extension
5th Nov 20217:00 amRNSPRM,INmune Bio presenting biomarker discovery data
3rd Nov 20214:41 pmRNSSecond Price Monitoring Extn
3rd Nov 20214:36 pmRNSPrice Monitoring Extension
26th Aug 20214:40 pmRNSSecond Price Monitoring Extn
26th Aug 20214:36 pmRNSPrice Monitoring Extension
29th Jul 20217:00 amRNSInterim Results
15th Jul 20214:41 pmRNSSecond Price Monitoring Extn
15th Jul 20214:35 pmRNSPrice Monitoring Extension
18th Jun 20211:14 pmRNSLoan amendment
8th Jun 202112:54 pmRNSGrant of Options and PDMR/director shareholdings
19th May 20216:01 pmRNSIssuance of key TMT Patent
18th May 20219:48 amRNSChange of Registered Office
12th May 20214:36 pmRNSPrice Monitoring Extension
7th May 20214:41 pmRNSSecond Price Monitoring Extn
7th May 20214:36 pmRNSPrice Monitoring Extension
6th May 20214:41 pmRNSSecond Price Monitoring Extn
6th May 20214:35 pmRNSPrice Monitoring Extension
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202111:57 amRNSResult of AGM
5th May 202111:00 amRNSAGM Statement
27th Apr 20214:40 pmRNSSecond Price Monitoring Extn
27th Apr 20214:35 pmRNSPrice Monitoring Extension
19th Apr 20215:25 pmRNSDirector/PDMR Shareholding
14th Apr 202112:18 pmRNSDirector/PDMR Shareholding
7th Apr 20214:40 pmRNSSecond Price Monitoring Extn
7th Apr 20214:35 pmRNSPrice Monitoring Extension
1st Apr 202112:48 pmRNSHolding(s) in Company
1st Apr 20219:34 amRNSInvestor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.